November 2, 2023
Every year, nine and a half million people die of cancer globally. Seventy percent of these deaths occur in low- and middle-income countries and are often from forms of the disease that are preventable or treatable, such as breast and cervical cancer. Lack of information and inadequate care mean that many cancer patients do not seek treatment until it is too late. When they do, healthcare facilities are frequently not equipped with the right tools, medications, or trained workers. Drugs and diagnostics are often poor quality and unaffordable. As a result, cancer is more than twice as lethal in low- and middle-income countries as it is in the United States.
In 2015, CHAI began partnering with the American Cancer Society (ACS) to increase access to high-quality and affordable treatment, strengthen health worker capacity, and help governments establish plans to comprehensively manage the disease. In 2017, CHAI and ACS announced a groundbreaking agreement with pharmaceutical manufacturers, which was then expanded in 2020 and 2021. With individual agreements with Biocon Biologics, Novartis, Pfizer, and Viatris, the Cancer Access Partnership offers affordable access to 26 lifesaving cancer treatments in 30 countries in sub-Saharan Africa and Asia.
The agreements will result in significant savings on high-quality medicines, including key chemotherapies, hormonal therapies, biologics, and supportive therapies essential for the treatment of 30 cancers. Learn more about the partnership here. We are also working with governments to better understand their cancer treatment needs and expand services, including treatment for pediatric, breast, and cervical cancers.
savings on 26 essential cancer treatments
more breast cancer patients treated in Ethiopia
Cancer Access Partnership expands in 2021 to increase access to treatment for 30 cancers in Africa and Asia